About this course
Several SARS-CoV-2 virus variants have emerged since the pandemic started. Alongside the threat of these emerging variants, the evidence for COVID-19 therapeutics has likewise grown.
In the last two years alone, several medications have been shown to prevent hospitalization among vulnerable groups who have non-severe COVID-19 infection. However, guidelines continue to change as some drugs are deemed ineffective for emerging COVID subvariants. This e-learning module reviews the most recent outpatient medications recommended by the WHO for non-severe COVID-19 infection, the mechanism of action of these drugs, their adverse effects, and summarizes the available evidence regarding these therapeutic options.
Upon completion of the educational activity, participants should be able to:
- Identify the most recent outpatient medications recommended by the WHO for non-severe COVID-19 infection
- Understand the mechanism of action of these drugs, their adverse effects, indications, and contraindications
- Review the available evidence regarding these therapeutic options
- WHO COVID-19 severity definitions
- Identifying patients at risk for hospitalization
- Risk factors for severe COVID-19 outcomes
- Recommended action points for management
- Active monitoring, preventive measures
- Consider therapeutic options
- Overview of outpatient medications
- Antivirals: Nirmatrelvir-Ritonavir, Remdesivir, Molnupiravir
- Monoclonal antibodies: Bamlanivimab-Etesevimab, Bebtelovimab, Casirivimab-Imdevimab, Sotrovimab
- Current WHO recommendations
- Recent updates
Keywords: COVID-19, COVID antivirals, nirmatrelvir ritonavir, molnupiravir, remdesivir, WHO recommendations
1 CPD Point Available
A certificate can be downloaded upon successful completion of the quiz. Please use the information on the
certificate to claim your CPD points.